Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303108 · ClinicalTrials.gov registry record · Phase 2
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
A Phase 2 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00303108 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 136 participants.
The verdict
NCT00303108, a Phase 2 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Interventions
- DRUG Carboplatin
- DRUG trastuzumab
- DRUG Pegylated liposomal doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2005-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303108
The ClinicalTrials.gov registry entry for NCT00303108 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00303108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303108 about?
NCT00303108 is a clinical study titled "Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer". The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
What is the current status of trial NCT00303108?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2005-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00303108?
The interventions under investigation include: Carboplatin (DRUG), trastuzumab (DRUG), Pegylated liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00303108?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.